Clinical Trial Update: A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients. [Phase 1]

View source ↗

Summary

First-in-human Phase 1 trial of GSK2336805 in healthy volunteers and single-dose administration in chronically infected Hepatitis C patients has completed. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GSK2336805

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED